Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer.

Braun, M S; Adab, Fawzi; Bradley, C; McAdam, K; Thomas, G; Wadd, N J; Rea, D; Philips, R; Twelves, C; Bozzino, J; MacMillan, C; Saunders, Mark P; Counsell, R; Anderson, Heather; McDonald, A; Stewart, J; Robinson, A; Davies, S; Richards, F J; Seymour, M T

Affiliation

Cancer Research UK Centre in Leeds, Cookridge Hospital, Leeds LS16 6QB, UK.

Issue Date

2003-10-06

Metadata

Show full item record

Abstract

We previously reported high activity for oxaliplatin and a modified de Gramont regimen (OxMdG) in a single centre study of patients with metastatic colorectal cancer. We now report results with a further 56 patients treated at 14 centres. Low rates of grade 3 and 4 toxicity were seen, with no toxic deaths. Objective response rates were CR/PR=53%; NC=34.7%; PD=12.2%. Median time to progression was 8.3 months and overall survival was 14.5 months. This regimen is more convenient than those based around the conventional de Gramont regimen but is highly active and well tolerated; it forms part of a current UK MRC phase 3 trial.

Citation

Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer. 2003, 89 (7):1155-8 Br. J. Cancer

Journal

British Journal of Cancer

URI

http://hdl.handle.net/10541/78833

DOI

10.1038/sj.bjc.6601237

PubMed ID

14520437

Type

Article

Language

ISSN

0007-0920

Collections

All Christie Publications